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Multiple myeloma is an incurable disease in many patients;
therefore, maintaining good quality of life (QOL) for the dura-
tion of the long-term treatment is important.Taste dysfunction
is reported to occur in 30 to 70% of patients receiving cancer
chemotherapy [1]. This adverse event affects the appetite of
patients; consequently, QOL of patients decreases. However, it
remains unclear about the association between taste dysfunc-
tion and anti-multiple myeloma drugs. In this study, reports
submitted to the US Food and Drug Administration (FDA)
Adverse Event Reporting System (FAERS) were reviewed to
assess taste dysfunction induced by the administration of anti-
multiple myeloma drugs.
Input data for this study were taken from public releases
of the FAERS database, covering the period from the fourth
quarter of 1997 through the first quarter of 2014. Following pre-
processing of FAERS data by elimination of duplicate records
as well as adjustments to standardize drug names, reports in-
volving bendamustine, bortezomib, cyclophosphamide,
dexamethasone, doxorubicin, lenalidomide, melphalan, pred-
nisolone, thalidomide, and vincristine were analyzed. Some of
the adverse events that have been defined as “taste and smell
disorders” in the Standardised MedDRA Queries (SMQs), version
18.0, i.e. ageusia, dysgeusia, gustometry abnormal, hallucina-
tion, hypergeusia, and hypogeusia, were focused on as
representative words for taste dysfunction in this study. Signals
in the data that signified a drug-associated adverse event were
detected via quantitative data mining algorithms. The algo-
rithm applied to this study was the reporting odds ratio (ROR).
The results were shown in Fig. 1. A signal for ageusia was
detected with lenalidomide, and its signal score was 1.84. As
for hypogeusia, signals were detected with bortezomib, dexa-
methasone, and lenalidomide, and signal scores suggested the
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same level in terms of association. Gender data were avail-
able for 4,864,737 of 5,274,242 (92.2%) reports, 1,883,921 reports
for males and 2,980,816 reports for females. The aforemen-
tioned signals were detected in males, but not in females. On
the other hand, there were no reports or signals for dysgeu-
sia, gustometry abnormal, hallucination, or hypergeusia. In this
study, the results suggest that lenalidomide has greater rel-
evance to taste dysfunction than the other drugs we analyzed,
and taste dysfunction induced by the administration of anti-
multiple myeloma drugs tends to more easily occur among
males.
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Fig. 1 – Signal scores for adverse events by anti-multiple myeloma drugs.
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